Ozempic lowers blood sugar and weight more than metformin, but they are usually partners, not rivals. In SUSTAIN 2, people already on metformin who added semaglutide 1 mg cut HbA1c by 1.6 points and lost 6.1 kg over 56 weeks. Metformin is a cheap generic pill and roughly weight-neutral; Ozempic costs $349 to $499 a month without insurance.
“Metformin vs Ozempic” is a slightly misleading framing, because the two aren’t competing for the same job. They’re different classes of drug, with different strengths, and in real diabetes care they’re frequently used together. The useful question isn’t which wins — it’s what each one is for.
Two different drugs, two different jobs
Metformin is a biguanide — an inexpensive oral pill that lowers glucose mainly by reducing the liver’s sugar output, with decades of safety data and a near-neutral effect on weight. Ozempic is semaglutide, a GLP-1 receptor agonist — a once-weekly injection that lowers glucose and powerfully reduces appetite. They lower blood sugar through completely different mechanisms, which is exactly why they combine well.
What the numbers show
In the SUSTAIN-2 trial (1,225 adults whose diabetes was not controlled on metformin, a thiazolidinedione or both), adding semaglutide to that background therapy cut HbA1c by 1.3 to 1.6 percentage points and reduced body weight by 4.3 to 6.1 kg (at the 0.5 and 1.0 mg doses) — against 0.5 points and 1.9 kg for the sitagliptin comparator, a treatment difference of up to −1.06 percentage points (95% CI −1.21 to −0.91) and −4.20 kg (95% CI −4.91 to −3.49) at 56 weeks.[1] The American Diabetes Association’s 2026 Standards rate metformin’s glucose-lowering as high and its weight effect as neutral (with potential for modest loss), and GLP-1 drugs as high to very high, with weight loss. Added to metformin, a GLP-1 drug usually lowers HbA1c by 1 to 2 points or more, against about 0.7 to 1.0 points for each oral class.[2] So on raw potency for both blood sugar and weight, semaglutide wins clearly.
| Metformin | Ozempic (semaglutide) | |
|---|---|---|
| Class | Biguanide | GLP-1 receptor agonist |
| Route | Oral, daily | Injection, weekly |
| Glucose-lowering | Modest, reliable | Greater (−1.3 to −1.6 pts added) |
| Weight | ≈ neutral | Meaningful loss (4–6 kg) |
| Cost | Very low (generic) | $349–$499/mo self-pay (October 2026); as little as $25 with coverage |
| Track record | Decades, first-line | Newer, potent |
The honest verdict
If you’re forced to compare them head to head, semaglutide is the more powerful drug for both blood sugar and weight, but metformin is cheaper, oral, weight-neutral, and has a far longer track record, which is why it remains a foundation for many people.[1][2] For many patients the realistic path is metformin first with a GLP-1 added when needed, while people with heart or kidney disease are often started on a GLP-1 drug sooner. It is rarely one instead of the other. Note this is Ozempic, the diabetes brand; for weight loss specifically the semaglutide brand is Wegovy (see Ozempic vs Wegovy). If metformin’s longevity angle interests you, see metformin and longevity; to compare GLP-1 options, our GLP-1 comparison tool and provider guide.